Media-OutReach Newswire GangaGen Secures additional US$7.9 Million from CARB-X for Pre-clinical Development of Novel Klebicins Targeting Nosocomial Pneumonia caused by Multidrug-resistant Klebsiella pneumoniae
VN-Index reverses and drops nearly 14 points as experts urge caution amid profit-taking and tariff uncertainty 1.